Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker Publication Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker CertaraFebruary 8, 2018
Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial Publication Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-concept, Randomised, Placebo-controlled Trial CertaraJanuary 15, 2018
Model-informed Drug Development for Malaria Therapeutics Publication Model-informed Drug Development for Malaria Therapeutics CertaraJanuary 6, 2018
How to Perform Level C IVIVC in Phoenix On-Demand Webinar How to Perform Level C IVIVC in Phoenix Step-by-step guidance for Level C IVIVC studies.CertaraDecember 13, 2017
Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies Publication Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies CertaraNovember 1, 2017
A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies Publication A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies CertaraOctober 30, 2017
Influence of Molecular Size on the Clearance of Antibody Fragments Publication Influence of Molecular Size on the Clearance of Antibody Fragments CertaraOctober 1, 2017
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal White Paper Drug Asset Evaluation: Increasing “Probability of Success” of a Deal Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…CertaraAugust 24, 2017
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Publication Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types CertaraAugust 1, 2017
Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Publication Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients CertaraJuly 15, 2017